How Much Does Addyi (Flibanserin) Cost in Tennessee in 2026?

Tennessee Retail Pricing for Brand-Name Addyi

The average cash price for a 30-day supply of brand-name Addyi at Tennessee retail pharmacies sits at $880 in 2026, matching the Sprout Pharmaceuticals list price. That figure has remained flat since the drug's 2015 FDA approval. Price variation between Tennessee pharmacies is minimal because there is no generic flibanserin on the U.S. market.

Flibanserin received FDA approval in August 2015 as the first drug indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval followed three phase III trials, including the BEGONIA trial (N=1,087), which demonstrated a statistically significant increase in satisfying sexual events (SSEs) of 0.8 per month over placebo across 24 weeks. The BEGONIA data also showed a 1.0-point reduction in distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) Item 13.

Tennessee patients paying out of pocket should know the $880 price applies at chains like CVS, Walgreens, and Kroger pharmacies statewide. Independent pharmacies in Nashville, Memphis, Knoxville, and Chattanooga typically match or come within $10 of that figure. No Tennessee-specific pricing legislation caps prescription drug costs for this medication.

Tennessee Medicaid and Addyi: No Coverage

TennCare, the state's Medicaid managed care program, does not cover Addyi. The drug is excluded from the preferred drug list. This means Tennessee Medicaid enrollees cannot obtain flibanserin through their TennCare benefits regardless of medical necessity documentation.

The exclusion reflects a pattern across most state Medicaid programs. A 2016 analysis published in the Journal of Managed Care & Specialty Pharmacy found that fewer than 10 state Medicaid programs had added flibanserin to their formularies within the first year after approval. Tennessee has not reversed that position as of May 2026. The reasoning cited by state pharmacy and therapeutics committees typically centers on the drug's modest effect size relative to cost: the BEGONIA trial showed an absolute increase of roughly 0.5 to 1.0 additional SSEs per month over placebo, which some payers consider below clinically meaningful thresholds.

For TennCare enrollees with HSDD, alternative covered options may include off-label bupropion or referral to cognitive behavioral therapy for sexual dysfunction. Neither carries the same mechanism of action. Flibanserin acts as a 5-HT1A agonist and 5-HT2A antagonist, modulating serotonergic and dopaminergic activity in the prefrontal cortex, a pharmacological profile distinct from any antidepressant.

Commercial Insurance Coverage in Tennessee

Most major commercial insurers operating in Tennessee, including BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, and Aetna, place Addyi on a specialty or non-preferred brand tier. Prior authorization is standard. The typical approval criteria require documentation of HSDD diagnosis in a premenopausal woman, failure of non-pharmacologic interventions, and confirmation that the patient is not taking moderate or strong CYP3A4 inhibitors.

According to Endocrine Society clinical guidance on female sexual dysfunction, the diagnosis of HSDD should include persistent low desire causing personal distress for at least six months, not attributable to a coexisting medical or psychiatric condition, relationship factors, or medication effects. Insurers in Tennessee generally follow these diagnostic boundaries when evaluating prior authorization requests.

Co-pays for commercially insured patients who obtain approval vary widely. Preferred plans may set a $75 to $150 monthly co-pay. Non-preferred tier placement can push that figure to $200 to $350. High-deductible health plans may require the full $880 until the deductible is met. Tennessee's individual marketplace plans through Healthcare.gov follow similar formulary structures, with most silver-tier plans requiring prior authorization and specialty-tier co-insurance of 25% to 40%.

Dr. Sheryl Kingsberg, a clinical psychologist and researcher who served as a principal investigator on the flibanserin trials, noted in a 2019 commentary: "The prior authorization burden for HSDD treatments creates a barrier that doesn't exist for male sexual dysfunction drugs, raising questions about equity in coverage."

Compounded Flibanserin in Tennessee: Legal and Available

Compounded flibanserin is legal in Tennessee through licensed 503A compounding pharmacies. These pharmacies operate under individual patient prescriptions and must comply with both FDA guidance under Section 503A of the Federal Food, Drug, and Cosmetic Act and Tennessee Board of Pharmacy regulations.

The cost difference is significant. Several telehealth platforms partnered with 503A compounding pharmacies offer flibanserin at drastically reduced prices, with some programs advertising the compounded formulation at no additional cost beyond a consultation or subscription fee. The compounded version typically uses the same active ingredient (flibanserin 100 mg) in capsule form rather than the branded tablet.

Tennessee patients considering compounded flibanserin should verify three things. First, confirm the compounding pharmacy holds a valid Tennessee Board of Pharmacy license. Second, ensure a legitimate provider-patient relationship exists, whether through in-person evaluation or a compliant telehealth visit. Third, ask whether the pharmacy conducts third-party potency and sterility testing. The FDA's compounding quality page outlines the regulatory framework distinguishing 503A (patient-specific) from 503B (outsourcing facility) operations.

One limitation: compounded drugs do not undergo the same bioequivalence testing as FDA-approved generics. The BEGONIA trial and the two other key trials (DAISY and VIOLET) were conducted using the branded formulation. No published trial data exist for compounded flibanserin specifically, though the active pharmaceutical ingredient is identical.

Telehealth Prescribing of Addyi in Tennessee

Tennessee law permits telehealth prescribing of flibanserin. The state updated its telemedicine statutes in 2021 to allow prescribing of non-controlled medications through audio-video consultations without a prior in-person visit. Flibanserin is not a scheduled controlled substance, so it qualifies.

Multiple national telehealth platforms serve Tennessee patients seeking flibanserin. These platforms typically bundle the consultation, prescription, and compounded medication into a single monthly fee. The process generally follows these steps: an online intake questionnaire, a synchronous video visit with a licensed prescriber, review of the REMS-related alcohol interaction counseling, and shipment of medication to the patient's Tennessee address.

The FDA-mandated REMS (Risk Evaluation and Mitigation Strategy) for brand-name Addyi requires prescribers to complete certification and counsel patients about the risks of hypotension and syncope when flibanserin is combined with alcohol. The REMS applies to the branded product. Compounded versions are not technically subject to the branded REMS, though responsible prescribers apply the same counseling regardless of formulation source.

A practical note for Tennessee telehealth patients: the FDA's 2023 final rule on prescribing via telehealth maintained flexibility for non-controlled substances. Tennessee's alignment with this federal framework means no additional state-level barriers exist for flibanserin telehealth prescriptions.

Sprout Pharmaceuticals Savings Card and Tennessee Discount Programs

Sprout Pharmaceuticals offers a manufacturer savings card for commercially insured patients. The card can reduce out-of-pocket costs to as low as $0 per month for eligible patients, with a maximum annual benefit that varies by program year. Tennessee residents with commercial insurance (not Medicare, Medicaid, or other government-funded plans) can enroll through the Addyi website or by calling Sprout's patient support line.

Eligibility requirements are straightforward. The patient must have commercial prescription drug coverage, a valid prescription from a REMS-certified prescriber, and must fill the prescription at a participating pharmacy. Tennessee chains including CVS, Walgreens, and Kroger Health pharmacies typically participate.

For uninsured Tennessee patients, the savings card does not apply. Alternative discount routes include GoodRx and RxSaver coupons, though these rarely bring the price below $700 for brand-name Addyi. The math favors compounded flibanserin for cash-pay patients. At roughly $30 to $90 per month through telehealth compounding programs versus $880 at retail, the annual savings can exceed $9,000.

The American College of Obstetricians and Gynecologists (ACOG) recognizes HSDD as a valid clinical diagnosis warranting treatment, a position that supports appeals when insurers deny coverage. Tennessee patients who receive a denial can file a formal appeal citing ACOG Practice Bulletin No. 213, which lists flibanserin as an FDA-approved pharmacotherapy option.

Clinical Considerations Before Starting Flibanserin

Flibanserin takes time to work. The BEGONIA trial measured endpoints at 24 weeks, and the FDA label recommends discontinuing the drug after 8 weeks if no improvement occurs. Tennessee prescribers should set this expectation during the initial consultation.

The alcohol interaction remains the most clinically significant safety concern. In a dedicated pharmacokinetic study referenced in the FDA label, combining flibanserin 100 mg with 0.4 g/kg ethanol (roughly two drinks) produced clinically significant drops in systolic blood pressure and increased rates of presyncope in 24% of female subjects versus 0% with placebo. Tennessee patients should understand this is not a theoretical risk.

Other drug interactions matter too. Moderate and strong CYP3A4 inhibitors, including fluconazole, erythromycin, and certain HIV protease inhibitors, are contraindicated with flibanserin. Grapefruit juice inhibits CYP3A4 and should be avoided. The FDA drug interaction guidance provides the complete CYP3A4 inhibitor list relevant to prescribing decisions.

Common adverse effects reported in the key trials at rates exceeding placebo: dizziness (11.4% vs. 2.2%), somnolence (11.2% vs. 3.1%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.5%). These figures come from pooled data across the three phase III trials, as summarized in the Addyi prescribing information. The bedtime dosing requirement exists specifically to mitigate the hypotension and somnolence risk.

Comparing Addyi to Vyleesi in Tennessee

Bremelanotide (Vyleesi), the only other FDA-approved drug for premenopausal HSDD, offers a different dosing model. It is an on-demand subcutaneous injection (1.75 mg, at least 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than 8 doses per month). The RECONNECT trial (N=1,247) showed a 0.7 increase in SSEs per month over placebo at 24 weeks.

In Tennessee, Vyleesi carries a list price of approximately $900 for a pack of four autoinjectors. A patient using 4 to 8 injections per month would spend $900 to $1,800 monthly at cash price. Tennessee Medicaid does not cover Vyleesi either. For patients who prefer daily oral dosing over injections, flibanserin remains the only option. For patients who want on-demand dosing and find flibanserin's daily commitment impractical, bremelanotide fills that gap.

Both drugs produced modest effect sizes in trials. A 2021 systematic review in the Annals of Internal Medicine concluded that both flibanserin and bremelanotide produced statistically significant but clinically small improvements in sexual desire and SSEs compared with placebo. The review noted the evidence was rated as low to moderate certainty.

Tennessee patients should discuss both options with their prescriber and weigh factors beyond price: route of administration, side-effect profiles (nausea is common with both; injection-site reactions occur with bremelanotide; hypotension and alcohol interaction are specific to flibanserin), and lifestyle compatibility.

Tennessee-Specific Pharmacy and Regulatory Notes

Tennessee Board of Pharmacy Rule 1140-02 governs compounding standards in the state. Any 503A pharmacy dispensing compounded flibanserin must hold an active Tennessee pharmacy license and comply with USP <795> standards for non-sterile compounding. Patients can verify a pharmacy's license status through the Tennessee Department of Health license verification portal.

Tennessee does not impose a state-level prescription drug price transparency law that would affect Addyi pricing. The state's 2024 legislative session introduced SB-1432 regarding pharmacy benefit manager reform, but the bill did not include provisions specific to sexual health medications.

For Tennessee patients near state borders, Arkansas, Mississippi, Alabama, Georgia, Virginia, Kentucky, Missouri, and North Carolina each have their own compounding and telehealth laws. Prescriptions filled across state lines must comply with the dispensing state's pharmacy regulations, not the patient's home state.